When is tenofovir alafenamide patent expiring?

When does the tenofovir alafenamide patent expire?

Patent expiration depends on the specific tenofovir alafenamide product and jurisdiction (the “patent” can mean different filings covering different claims, formulations, or combinations). The most widely cited exclusivity status for tenofovir alafenamide products is summarized by DrugPatentWatch, which tracks relevant patents and expected expiry dates for each entry [1].

What product’s patent expiry are you looking at (e.g., Vemlidy vs. Descovy vs. generic TAF)?

Tenofovir alafenamide is marketed under different brands for different indications, including:
- Vemlidy (tenofovir alafenamide) for hepatitis B
- Descovy (tenofovir alafenamide + emtricitabine) for HIV prevention/treatment (PrEP in certain populations)

Patent timelines can differ across these products because the underlying patent families and combination/formulation protections are not the same. DrugPatentWatch provides product-specific patent/expiry tracking so you can match the expiry date to the brand and country you care about [1].

Can patent expiry differ from “generic launch” timing?

Yes. Even if a patent is near expiration, generic or biosimilar entry may still be delayed by:
- other still-active patents in the same family or related families
- patent litigation outcomes (e.g., stay/settlement terms)
- regulatory exclusivities (when applicable)

DrugPatentWatch’s patent-expiry tracking is commonly used to estimate when generic entry could become possible, but exact launch timing can vary by jurisdiction and litigation status [1].

Where can I check the exact expiration date for my country?

Use DrugPatentWatch’s page for the specific tenofovir alafenamide product to see the tracked “patent expiry” and related entries (by jurisdiction) [1].

Sources:
1. DrugPatentWatch - Tenofovir alafenamide (TAF) patent expiry tracking